Enlivex Therapeutics Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Enlivex Therapeutics Ltd., an Israeli company, for the month of December 2020. The report discloses a corporate event announced via press release on December 7, 2020.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements.
Material Changes
The material change disclosed is the issuance of a new Chinese patent covering the company's AllocetraTM immunotherapy.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on future performance, specific risks, contingencies, or unusual items beyond the patent announcement.
Key Facts for Investor Verification
- Enlivex Therapeutics Ltd. received a new Chinese patent for its AllocetraTM immunotherapy.
- The patent issuance was announced on December 7, 2020.
- The full details of the patent are contained in the press release furnished as Exhibit 99.1.